# Jade Biosciences, Inc.: Phase 3 study in IgA Nephropathy (IgAN) (480 participants)

**Score:** 90/100

| Field | Value |
|---|---|
| Sponsor | Jade Biosciences, Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A Nephropathy |
| NCT ID | NCT07902817 |
| Phase | Phase 3 |
| Status | recruiting |
| Conditions | IgA Nephropathy (IgAN) |
| Intervention types | drug |
| Target enrollment | 480 |
| Site countries | United States |
| Posted | 2026-10-29 |
| Planned start | 2026-12 |
| Event | Newly registered study |
| Event date | 2026-10-29 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Phase 3: multi-site, larger budget.
- 480 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07902817). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.